This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Singaram, V. Articles by Pratley, R. Search for Related Content PubMed PubMed Citation Articles by Singaram, V. Articles by Pratley, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Social Bookmarking                         What's this?

The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?

Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, US.

Richard Pratley

Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, US.

Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular disease (CVD). This complication accounts for much of the increased morbidity, mortality and costs of care associated with diabetes. Hypertension, dyslipidaemia, a pro-inflammatory phenotype, abnormal fibrinolysis and platelet activation, insulin resistance and high blood glucose concentrations all contribute to the increased risk of macrovascular disease in diabetes. Although reducing low-density lipopro-tein (LDL)-cholesterol, controlling blood pressure, angiotensin-converting enzyme (ACE) inhibitors and aspirin have been shown to decrease CVD in diabetes, it is less clear that lowering glucose levels decreases risk. The PROactive trial was undertaken to test whether treatment with the thiazolidinedione pioglitazone could decrease the number of CVD events in high-risk patients with T2DM.

Key Words: glycaemic control • macrovascular disease • pioglitazone • PROactive trial

Diabetes and Vascular Disease Research, Vol. 4, No. 3, 237-240 (2007)
DOI: 10.3132/dvdr.2007.047


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?